LATEST UPDATES » Big Data, Bigger Disease Management and Current preparations to manage the Future Health of Singaporeans       » Big Data in Clinical Research Sector       » Professor Yuk-ling Yung receives Gerard P. Kuiper Prize       » AXA Assistance on Regenerative Medicine       » Singtel – Singapore Cancer Society Race against Cancer 2015       » Jardiance® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death      
Immune Design and Medicago announce license agreement and collaboration to develop novel adjuvanted pandemic influenza vaccines
Immune Design, a leader in the field of therapeutic vaccines for cancer, infectious diseases and allergy, and Medicago Inc, a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), have entered a license agreement providing Medicago the use and commercialization of Immune Design's proprietary synthetic Toll-like Receptor 4 agonist, Glucopyranosyl Lipid A (GLA). Medicago has the option to use Immune Design's molecular adjuvant in its vaccines for various pandemic influenza strains.

Under the terms of the agreement, Immune Design has granted Medicago a worldwide, non-exclusive license to research, develop, and commercialize GLA as a component of its VLP-based vaccines in the field of pandemic influenza. Other terms were not disclosed.

“We are pleased to enter into this collaboration with Medicago and allow for our proprietary adjuvant to be utilized in their vaccine candidates for pandemic influenza,” states Carlos Paya, MD, PhD, Immune Design's President and Chief Executive Officer. “Medicago has demonstrated a track record to date, of rapid and successful vaccine candidates design and production which have them at the forefront of next generation vaccine development.”

“The established clinical safety and immunogenicity profile of Immune Design's synthetic TLR4 agonist, GLA, make it an ideal adjuvant for our VLP-based influenza vaccine candidates,” said Andy Sheldon, Medicago's President and Chief Executive Officer.  “We will further investigate the use of both formulated GLA and alum in our Phase II H5N1 trial which was recently initiated with results expected during the summer of 2013.”

Medicago's first vaccine candidate in the field, which targets the H5N1 influenza strain, completed a successful U.S. Phase I study which was conducted with the Infectious Disease Research Institute (IDRI), earlier this year. In that study, all three configurations of adjuvant and route of administration (I.D., Alum, and GLA-AF) for 20ug of the H5N1 vaccine candidate induced a solid immune response against the H5N1 viral strain that exceeded the CHMP immunogenicity criteria for licensure of influenza vaccines. Medicago recently initiated a Phase II study of its H5N1 VLP in combination with both the GLA and alum adjuvants with results expected in the summer of 2013.

Medicago also recently announced the production of a H7N9 VLP vaccine candidate which includes formulated GLA or alum, making Medicago the first company to successfully produce a VLP vaccine candidate against the emerging strain. Medicago and Immune Design are collaborating to conduct preclinical studies of the H7N9 VLP-GLA combination.

Click here for the complete issue.


Credits to Sony Computer Entertainment and click here for behind the scenes.

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy